## Timothy B Hallett

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7028017/publications.pdf

Version: 2024-02-01

192 papers 13,431 citations

53 h-index 30277 107 g-index

200 all docs

200 docs citations

200 times ranked 17609 citing authors

#	Article	IF	CITATIONS
1	Understanding the Potential Impact of Different Drug Properties on Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Transmission and Disease Burden: A Modelling Analysis. Clinical Infectious Diseases, 2022, 75, e224-e233.	2.9	10
2	Socio-demographic factors associated with early antenatal care visits among pregnant women in Malawi: 2004–2016. PLoS ONE, 2022, 17, e0263650.	1.1	4
3	Perspectives on the use of modelling and economic analysis to guide HIV programmes in sub-Saharan Africa. Lancet HIV,the, 2022, 9, e517-e520.	2.1	3
4	Cost-effectiveness of easy-access, risk-informed oral pre-exposure prophylaxis in HIV epidemics in sub-Saharan Africa: a modelling study. Lancet HIV,the, 2022, 9, e353-e362.	2.1	19
5	Clinical Characteristics and Predictors of Outcomes of Hospitalized Patients With Coronavirus Disease 2019 in a Multiethnic London National Health Service Trust: A Retrospective Cohort Study. Clinical Infectious Diseases, 2021, 73, e4047-e4057.	2.9	81
6	The Potential Impact of Long-Acting Cabotegravir for HIV Prevention in South Africa: A Mathematical Modeling Study. Journal of Infectious Diseases, 2021, 224, 1179-1186.	1.9	19
7	Investment Case for a Comprehensive Package of Interventions Against Hepatitis B in China: Applied Modeling to Help National Strategy Planning. Clinical Infectious Diseases, 2021, 72, 743-752.	2.9	25
8	Estimating the health impact of vaccination against ten pathogens in 98 low-income and middle-income countries from 2000 to 2030: a modelling study. Lancet, The, 2021, 397, 398-408.	6.3	144
9	Economic and epidemiological evaluation of interventions to reduce the burden of hepatitis C in Yunnan province, China. PLoS ONE, 2021, 16, e0245288.	1.1	5
10	Characteristics and outcomes of clinically diagnosed RT-PCR swab negative COVID-19: a retrospective cohort study. Scientific Reports, 2021, 11, 2455.	1.6	8
11	Consensus statement on the role of health systems in advancing the long-term well-being of people living with HIV. Nature Communications, 2021, 12, 4450.	5.8	67
12	Potential impact of intervention strategies on COVID-19 transmission in Malawi: a mathematical modelling study. BMJ Open, 2021, 11, e045196.	0.8	8
13	Lives saved with vaccination for 10 pathogens across 112 countries in a pre-COVID-19 world. ELife, 2021, 10, .	2.8	50
14	The global burden of chronic hepatitis B virus infection: comparison of country-level prevalence estimates from four research groups. International Journal of Epidemiology, 2021, 50, 560-569.	0.9	29
15	Modeling the epidemiological impact of the UNAIDS 2025 targets to end AIDS as a public health threat by 2030. PLoS Medicine, 2021, 18, e1003831.	3.9	41
16	The impact of the timely birth dose vaccine on the global elimination of hepatitis B. Nature Communications, 2021, 12, 6223.	5.8	48
17	How can the public health impact of vaccination be estimated?. BMC Public Health, 2021, 21, 2049.	1.2	11
18	Progress towards elimination of mother-to-child transmission of hepatitisÂB virus infection in China: a modelling analysis. Bulletin of the World Health Organization, 2021, 99, 10-18.	1.5	10

#	Article	IF	Citations
19	On discount rates for economic evaluations in global health. Health Policy and Planning, 2020, 35, 107-114.	1.0	71
20	Mapping the Current and Future Noncommunicable Disease Burden in Kenya by Human Immunodeficiency Virus Status: A Modeling Study. Clinical Infectious Diseases, 2020, 71, 1864-1873.	2.9	15
21	Factors associated with healthcare seeking behaviour for children in Malawi: 2016. Tropical Medicine and International Health, 2020, 25, 1486-1495.	1.0	11
22	The impact of scaling up cervical cancer screening and treatment services among women living with HIV in Kenya: a modelling study. BMJ Global Health, 2020, 5, e001886.	2.0	10
23	Potential impact of the COVID-19 pandemic on HIV, tuberculosis, and malaria in low-income and middle-income countries: a modelling study. The Lancet Global Health, 2020, 8, e1132-e1141.	2.9	573
24	Modelling hepatitis B virus infection and impact of timely birth dose vaccine: A comparison of two simulation models. PLoS ONE, 2020, 15, e0237525.	1.1	8
25	Potential effects of disruption to HIV programmes in sub-Saharan Africa caused by COVID-19: results from multiple mathematical models. Lancet HIV,the, 2020, 7, e629-e640.	2.1	295
26	Towards evidenceâ€based integration of services for HIV, nonâ€communicable diseases and substance use: insights from modelling. Journal of the International AIDS Society, 2020, 23, e25525.	1.2	7
27	Understanding the impact of interruptions to HIV services during the COVID-19 pandemic: A modelling study. EClinicalMedicine, 2020, 26, 100483.	3.2	44
28	Practical metrics for establishing the health benefits of research to support research prioritisation. BMJ Global Health, 2020, 5, e002152.	2.0	3
29	SARS-CoV-2 infection prevalence on repatriation flights from Wuhan City, China. Journal of Travel Medicine, 2020, 27, .	1.4	5
30	Responding to the ECHO trial results: modelling the potential impact of changing contraceptive method mix on HIV and reproductive health in South Africa. Journal of the International AIDS Society, 2020, 23, e25620.	1.2	5
31	Explaining age disparities in tuberculosis burden in Taiwan: a modelling study. BMC Infectious Diseases, 2020, 20, 191.	1.3	8
32	ECHO: context and limitations. Lancet, The, 2020, 395, e25-e26.	6.3	2
33	Improving risk perception and uptake of voluntary medical male circumcision with peer-education sessions and incentives, in Manicaland, East Zimbabwe: study protocol for a pilot randomised trial. Trials, 2020, 21, 108.	0.7	5
34	Estimating the effects of non-pharmaceutical interventions on COVID-19 in Europe. Nature, 2020, 584, 257-261.	13.7	2,558
35	On time horizons in health economic evaluations. Health Policy and Planning, 2020, 35, 1237-1243.	1.0	40
36	The potential impact of urine-LAM diagnostics on tuberculosis incidence and mortality: A modelling analysis. PLoS Medicine, 2020, 17, e1003466.	3.9	10

#	Article	IF	CITATIONS
37	A cross-sectional study on factors associated with health seeking behaviour of Malawians aged 15+ years in 2016. Malawi Medical Journal, 2020, 32, 205-212.	0.2	1
38	Pricing viral hepatitis as part of universal health coverage. The Lancet Global Health, 2019, 7, e1148-e1149.	2.9	0
39	Costâ€perâ€diagnosis as a metric for monitoring costâ€effectiveness of HIV testing programmes in lowâ€income settings in southern Africa: health economic and modelling analysis. Journal of the International AIDS Society, 2019, 22, e25325.	1.2	20
40	Application of the HIV prevention cascade to identify, develop and evaluate interventions to improve use of prevention methods: examples from a study in east Zimbabwe. Journal of the International AIDS Society, 2019, 22, e25309.	1.2	21
41	The impact, cost and costâ€effectiveness of oral preâ€exposure prophylaxis in subâ€Saharan Africa: a scoping review of modelling contributions and way forward. Journal of the International AIDS Society, 2019, 22, e25390.	1.2	24
42	The Global Fund impact. Lancet, The, 2019, 394, 1708-1709.	6.3	1
43	Metrics and benchmarks for HIV transition. Lancet HIV, the, 2019, 6, e150.	2.1	2
44	The impact and cost-effectiveness of combined HIV prevention scenarios among transgender women sex-workers in Lima, Peru: a mathematical modelling study. Lancet Public Health, The, 2019, 4, e127-e136.	4.7	21
45	Scaling up prevention and treatment towards the elimination of hepatitis C: a global mathematical model. Lancet, The, 2019, 393, 1319-1329.	6.3	212
46	The potential impact of a "curative intervention―for HIV: a modelling study. Global Health Research and Policy, 2019, 4, 2.	1.4	12
47	Building a tuberculosis-free world: The Lancet Commission on tuberculosis. Lancet, The, 2019, 393, 1331-1384.	6.3	257
48	Assessing tuberculosis control priorities in high-burden settings: a modelling approach. The Lancet Global Health, 2019, 7, e585-e595.	2.9	58
49	Estimating HIV incidence from surveillance data indicates a second wave of infections in Brazil. Epidemics, 2019, 27, 77-85.	1.5	13
50	Response to Questionable assumptions mar modelling of Kenya homeâ€based testing campaigns ―a comment on "Optimal timing of HIV homeâ€based counselling and testing rounds in Western Kenya― (Olney etÂal. 2018). Journal of the International AIDS Society, 2019, 22, e25231.	1.2	0
51	Determinants of survival of people living with HIV/AIDS on antiretroviral therapy in Brazil 2006–2015. BMC Infectious Diseases, 2019, 19, 206.	1.3	41
52	Targeting and vaccine durability are key for population-level impact and cost-effectiveness of a pox-protein HIV vaccine regimen in South Africa. Vaccine, 2019, 37, 2258-2267.	1.7	13
53	The influence of constraints on the efficient allocation of resources for HIV prevention. Aids, 2019, 33, 1241-1246.	1.0	6
54	What impact could DMPA use have had in South Africa and how might its continued use affect the future of the HIV epidemic?. Journal of the International AIDS Society, 2019, 22, e25414.	1,2	6

#	Article	IF	Citations
55	Improving risk perception and uptake of pre-exposure prophylaxis (PrEP) through interactive feedback-based counselling with and without community engagement in young women in Manicaland, East Zimbabwe: study protocol for a pilot randomized trial. Trials, 2019, 20, 668.	0.7	14
56	The Estimation and Projection Package Age-Sex Model and the r-hybrid model. Aids, 2019, 33, S235-S244.	1.0	30
57	HIV prevention cascades: a unifying framework to replicate the successes of treatment cascades. Lancet HIV,the, 2019, 6, e60-e66.	2.1	56
58	National responses to global health targets: exploring policy transfer in the context of the UNAIDS †90†90†treatment targets in Ghana and Uganda. Health Policy and Planning, 2018, 33, 17-33.	1.0	10
59	Cardiovascular Disease Prevention Policy in Human Immunodeficiency Virus: Recommendations From a Modeling Study. Clinical Infectious Diseases, 2018, 66, 743-750.	2.9	22
60	Frontloading <scp>HIV</scp> financing maximizes the achievable impact of <scp>HIV</scp> prevention. Journal of the International AIDS Society, 2018, 21, e25087.	1.2	6
61	The growing burden of noncommunicable disease among persons living with HIV in Zimbabwe. Aids, 2018, 32, 773-782.	1.0	51
62	Cost-effectiveness of public-health policy options in the presence of pretreatment NNRTI drug resistance in sub-Saharan Africa: a modelling study. Lancet HIV, the, 2018, 5, e146-e154.	2.1	61
63	Targeting the right interventions to the right people and places. Aids, 2018, 32, 957-963.	1.0	36
64	The investment case for hepatitis B and C in South Africa: adaptation and innovation in policy analysis for disease program scale-up. Health Policy and Planning, 2018, 33, 528-538.	1.0	34
65	The importance of local epidemic conditions in monitoring progress towards HIV epidemic control in Kenya: a modelling study. Journal of the International AIDS Society, 2018, 21, e25203.	1.2	1
66	Appraising the value of evidence generation activities: an HIV modelling study. BMJ Global Health, 2018, 3, e000488.	2.0	7
67	The emerging health impact of voluntary medical male circumcision in Zimbabwe: An evaluation using three epidemiological models. PLoS ONE, 2018, 13, e0199453.	1.1	19
68	Epidemiological metrics and benchmarks for a transition in the HIV epidemic. PLoS Medicine, 2018, 15, e1002678.	3.9	59
69	Modelling the effect of discontinuing universal Bacillus Calmette-Guérin vaccination in an intermediate tuberculosis burden setting. Vaccine, 2018, 36, 5902-5909.	1.7	4
70	Optimal timing of HIV homeâ€based counselling and testing rounds in Western Kenya. Journal of the International AIDS Society, 2018, 21, e25142.	1.2	5
71	Treatment of HIV for the Prevention of Transmission in Discordant Couples and at the Population Level. Advances in Experimental Medicine and Biology, 2018, 1075, 125-162.	0.8	12
72	Could misreporting of condom use explain the observed association between injectable hormonal contraceptives and HIV acquisition risk?. Contraception, 2017, 95, 424-430.	0.8	11

#	Article	IF	Citations
73	Community-based screening and treatment for chronic hepatitis B in sub-Saharan Africa – Authors' reply. The Lancet Global Health, 2017, 5, e35.	2.9	1
74	PrEP for key populations in combination HIV prevention in Nairobi: a mathematical modelling study. Lancet HIV,the, 2017, 4, e214-e222.	2.1	37
75	Editorial. Aids, 2017, 31, S1-S4.	1.0	7
76	Introducing optimism to models of resource allocation to reduce HIV incidence – Authors' reply. Lancet HIV,the, 2017, 4, e12.	2.1	0
77	Does nonlocal women's attendance at antenatal clinics distort HIV prevalence surveillance estimates in pregnant women in Zimbabwe?. Aids, 2017, 31, S95-S102.	1.0	5
78	<scp>HIV</scp> prevention where it is needed most: comparison of strategies for the geographical allocation of interventions. Journal of the International AIDS Society, 2017, 20, e25020.	1.2	14
79	Consequences of a changing US strategy in the global HIV investment landscape. Aids, 2017, 31, F19-F23.	1.0	7
80	Documenting and explaining the HIV decline in east Zimbabwe: the Manicaland General Population Cohort. BMJ Open, 2017, 7, e015898.	0.8	34
81	Projections of non-communicable disease and health care costs among HIV-positive persons in Italy and the U.S.A.: A modelling study. PLoS ONE, 2017, 12, e0186638.	1.1	59
82	Economic evaluations of HBV testing and treatment strategies and applicability to low and middle-income countries. BMC Infectious Diseases, 2017, 17, 692.	1.3	16
83	A reconfiguration of the sex trade: How social and structural changes in eastern Zimbabwe left women involved in sex work and transactional sex more vulnerable. PLoS ONE, 2017, 12, e0171916.	1.1	19
84	The potential impact and cost of focusing HIV prevention on young women and men: A modeling analysis in western Kenya. PLoS ONE, 2017, 12, e0175447.	1.1	17
85	The impact of HCV therapy in a high HIV-HCV prevalence population: A modeling study on people who inject drugs in Ho Chi Minh City, Vietnam. PLoS ONE, 2017, 12, e0177195.	1.1	9
86	Effectiveness and Cost-Effectiveness of Treatment as Prevention for HIV., 2017,, 91-111.		4
87	Cost-Effectiveness of Interventions to Prevent HIV Acquisition. , 2017, , 137-155.		8
88	Gender-Specific Combination HIV Prevention for Youth in High-Burden Settings: The MP3 Youth Observational Pilot Study Protocol. JMIR Research Protocols, 2017, 6, e22.	0.5	8
89	PrEP as a feature in the optimal landscape of combination HIV prevention in subâ€6aharan Africa. Journal of the International AIDS Society, 2016, 19, 21104.	1.2	25
90	The HIV prevention cascade: integrating theories of epidemiological, behavioural, and social science into programme design and monitoring. Lancet HIV,the, 2016, 3, e318-e322.	2.1	121

#	Article	IF	Citations
91	Cost-effectiveness of community-based screening and treatment for chronic hepatitis B in The Gambia: an economic modelling analysis. The Lancet Global Health, 2016, 4, e568-e578.	2.9	91
92	Providing a conceptual framework for HIV prevention cascades and assessing feasibility of empirical measurement with data from east Zimbabwe: a case study. Lancet HIV, the, 2016, 3, e297-e306.	2.1	64
93	Optimum resource allocation to reduce HIV incidence across sub-Saharan Africa: a mathematical modelling study. Lancet HIV,the, 2016, 3, e441-e448.	2.1	70
94	Requirements for global elimination of hepatitis B: a modelling study. Lancet Infectious Diseases, The, 2016, 16, 1399-1408.	4.6	279
95	Maximising HIV prevention by balancing the opportunities of today with the promises of tomorrow: a modelling study. Lancet HIV,the, 2016, 3, e289-e296.	2.1	62
96	Evaluating strategies to improve HIV care outcomes in Kenya: a modelling study. Lancet HIV, the, 2016, 3, e592-e600.	2.1	31
97	Identifying Key Drivers of the Impact of an HIV Cure Intervention in Sub-Saharan Africa. Journal of Infectious Diseases, 2016, 214, 73-79.	1.9	13
98	Respiratory co-morbidities in people with HIV. Lancet Infectious Diseases, The, 2016, 16, 152.	4.6	5
99	HCV and HIV: shared challenges, shared solutions. Lancet Infectious Diseases, The, 2016, 16, 755-756.	4.6	4
100	The Incidence Patterns Model to Estimate the Distribution of New HIV Infections in Sub-Saharan Africa: Development and Validation of a Mathematical Model. PLoS Medicine, 2016, 13, e1002121.	3.9	16
101	How Much Do We Know about Drug Resistance Due to PrEP Use? Analysis of Experts' Opinion and Its Influence on the Projected Public Health Impact. PLoS ONE, 2016, 11, e0158620.	1.1	19
102	Seasonal PrEP for partners of migrant miners in southern Mozambique: a highly focused PrEP intervention. Journal of the International AIDS Society, 2015, 18, 19946.	1.2	35
103	A Comparison of South African National HIV Incidence Estimates: A Critical Appraisal of Different Methods. PLoS ONE, 2015, 10, e0133255.	1.1	56
104	Sustainable HIV treatment in Africa through viral-load-informed differentiated care. Nature, 2015, 528, S68-S76.	13.7	141
105	Assessment of epidemic projections using recent HIV survey data in South Africa: a validation analysis of ten mathematical models of HIV epidemiology in the antiretroviral therapy era. The Lancet Global Health, 2015, 3, e598-e608.	2.9	46
106	Future challenges for clinical care of an ageing population infected with HIV: a modelling study. Lancet Infectious Diseases, The, 2015, 15, 810-818.	4.6	634
107	Estimating the range of potential epidemiological impact of pre-exposure prophylaxis. Aids, 2015, 29, 733-738.	1.0	17
108	Cost-effectiveness of community-based strategies to strengthen the continuum of HIV care in rural South Africa: a health economic modelling analysis. Lancet HIV,the, 2015, 2, e159-e168.	2.1	59

#	Article	IF	CITATIONS
109	Estimating the Cost-Effectiveness of Pre-Exposure Prophylaxis to Reduce HIV-1 and HSV-2 Incidence in HIV-Serodiscordant Couples in South Africa. PLoS ONE, 2015, 10, e0115511.	1.1	17
110	How Can We Get Close to Zero? The Potential Contribution of Biomedical Prevention and the Investment Framework towards an Effective Response to HIV. PLoS ONE, 2014, 9, e111956.	1.1	67
111	The Distribution of Sex Acts and Condom Use within Partnerships in a Rural Sub-Saharan African Population. PLoS ONE, 2014, 9, e88378.	1.1	17
112	Increasing the use of secondâ€ine therapy is a costâ€effective approach to prevent the spread of drugâ€resistant HIV: a mathematical modelling study. Journal of the International AIDS Society, 2014, 17, 19164.	1.2	26
113	Why the proportion of transmission during early-stage HIV infection does not predict the long-term impact of treatment on HIV incidence. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 16202-16207.	3.3	42
114	Modeling the Impact of Interventions Along the HIV Continuum of Care in Newark, New Jersey. Clinical Infectious Diseases, 2014, 58, 274-284.	2.9	25
115	How do different eligibility guidelines for antiretroviral therapy affect the cost–effectiveness of routine viral load testing in sub-Saharan Africa?. Aids, 2014, 28, S73-S83.	1.0	22
116	How Much Do We Know about Drug Resistance Due to PrEP Use? Analysis of Experts' Opinion and Its Influence on the Projected Public Health Impact. AIDS Research and Human Retroviruses, 2014, 30, A161-A161.	0.5	0
117	Recent HIV prevalence trends among pregnant women and all women in sub-Saharan Africa. Aids, 2014, 28, S507-S514.	1.0	66
118	The Price of Sex: Condom Use and the Determinants of the Price of Sex Among Female Sex Workers in Eastern Zimbabwe. Journal of Infectious Diseases, 2014, 210, S569-S578.	1.9	44
119	Incorporating incidence information within the UNAIDS Estimation and Projection Package framework. Aids, 2014, 28, S515-S522.	1.0	12
120	Transformation of HIV from pandemic to low-endemic levels: a public health approach to combination prevention. Lancet, The, 2014, 384, 272-279.	6.3	107
121	Research on hormonal contraception and HIV – Authors' reply. Lancet, The, 2014, 383, 305-306.	6.3	5
122	Beware of using invalid transmission models to guide HIV health policy – Authors' reply. The Lancet Global Health, 2014, 2, e261.	2.9	1
123	Maximising the effect of combination HIV prevention in Kenya – Authors' reply. Lancet, The, 2014, 384, 1426-1427.	6.3	1
124	Maximising the effect of combination HIV prevention through prioritisation of the people and places in greatest need: a modelling study. Lancet, The, 2014, 384, 249-256.	6.3	206
125	Cost-effectiveness of different strategies to monitor adults on antiretroviral treatment: a combined analysis of three mathematical models. The Lancet Global Health, 2014, 2, e35-e43.	2.9	44
126	Health benefits, costs, and cost-effectiveness of earlier eligibility for adult antiretroviral therapy and expanded treatment coverage: a combined analysis of 12 mathematical models. The Lancet Global Health, 2014, 2, e23-e34.	2.9	188

#	Article	IF	CITATIONS
127	Modeling the impact of early antiretroviral therapy for adults coinfected with HIV and hepatitis B or C in South Africa. Aids, 2014, 28, S35-S46.	1.0	23
128	Estimating HIV incidence from case-report data. Aids, 2014, 28, S489-S496.	1.0	9
129	Using modeling to inform international guidelines for antiretroviral treatment. Aids, 2014, 28, S1-S4.	1.0	24
130	Next steps for research on hormonal contraception and HIV. Lancet, The, 2013, 382, 1467-1469.	6.3	21
131	Antiretroviral treatment of HIV-1 prevents transmission of HIV-1: where do we go from here?. Lancet, The, 2013, 382, 1515-1524.	6.3	202
132	Cost-effectiveness of point-of-care viral load monitoring of antiretroviral therapy in resource-limited settings. Aids, 2013, 27, 1483-1492.	1.0	45
133	Preexposure prophylaxis will have a limited impact on HIV-1 drug resistance in sub-Saharan Africa. Aids, 2013, 27, 2943-2951.	1.0	61
134	Putting the burden of HIV in context. Aids, 2013, 27, 2161-2162.	1.0	2
135	Elimination of HIV in South Africa through Expanded Access to Antiretroviral Therapy: A Model Comparison Study. PLoS Medicine, 2013, 10, e1001534.	3.9	124
136	Financing Essential HIV Services: A New Economic Agenda. PLoS Medicine, 2013, 10, e1001567.	3.9	36
137	Early HIV Infection in the United States: A Virus's Eye View. PLoS Medicine, 2013, 10, e1001569.	3.9	2
138	Modelling the global competing risks of a potential interaction between injectable hormonal contraception and HIV risk. Aids, 2013, 27, 105-113.	1.0	63
139	Only a fraction of new HIV infections occur within identifiable stable discordant couples in sub-Saharan Africa. Aids, 2013, 27, 251-260.	1.0	39
140	The new role of antiretrovirals in combination HIV prevention. Aids, 2013, 27, 447-458.	1.0	122
141	A Side Door Into Care Cascade for HIV-Infected Patients?. Journal of Acquired Immune Deficiency Syndromes (1999), 2013, 63, S228-S232.	0.9	87
142	Are Thai MSM Willing to Take PrEP for HIV Prevention? An Analysis of Attitudes, Preferences and Acceptance. PLoS ONE, 2013, 8, e54288.	1.1	79
143	Migration and the Transmission of STIs., 2013,, 65-75.		2
144	Understanding the Potential Impact of a Combination HIV Prevention Intervention in a Hyper-Endemic Community. PLoS ONE, 2013, 8, e54575.	1.1	36

#	Article	IF	CITATIONS
145	Monitoring of Antiretroviral Therapy and Mortality in HIV Programmes in Malawi, South Africa and Zambia: Mathematical Modelling Study. PLoS ONE, 2013, 8, e57611.	1.1	27
146	Analytic Review of Modeling Studies of ARV Based PrEP Interventions Reveals Strong Influence of Drug-Resistance Assumptions on the Population-Level Effectiveness. PLoS ONE, 2013, 8, e80927.	1.1	12
147	Understanding the modes of tranmission model of new HIV infection and its use in prevention planning. Bulletin of the World Health Organization, 2012, 90, 831-838.	1.5	56
148	HIV Treatment as Prevention: Principles of Good HIV Epidemiology Modelling for Public Health Decision-Making in All Modes of Prevention and Evaluation. PLoS Medicine, 2012, 9, e1001239.	3.9	38
149	The Potential Impact of Pre-Exposure Prophylaxis for HIV Prevention among Men Who Have Sex with Men and Transwomen in Lima, Peru: A Mathematical Modelling Study. PLoS Medicine, 2012, 9, e1001323.	3.9	76
150	HIV Treatment as Prevention: Systematic Comparison of Mathematical Models of the Potential Impact of Antiretroviral Therapy on HIV Incidence in South Africa. PLoS Medicine, 2012, 9, e1001245.	3.9	324
151	Distinct HIV discordancy patterns by epidemic size in stable sexual partnerships in sub-Saharan Africa. Sexually Transmitted Infections, 2012, 88, 51-57.	0.8	80
152	HIV Treatment as Prevention: Optimising the Impact of Expanded HIV Treatment Programmes. PLoS Medicine, 2012, 9, e1001258.	3.9	50
153	HIV Treatment as Prevention: Considerations in the Design, Conduct, and Analysis of Cluster Randomized Controlled Trials of Combination HIV Prevention. PLoS Medicine, 2012, 9, e1001250.	3.9	58
154	The effect of changes in condom usage and antiretroviral treatment coverage on human immunodeficiency virus incidence in South Africa: a model-based analysis. Journal of the Royal Society Interface, 2012, 9, 1544-1554.	1.5	61
155	Sex with stitches. Aids, 2012, 26, 749-756.	1.0	35
156	Viral load monitoring of antiretroviral therapy, cohort viral load and HIV transmission in Southern Africa. Aids, 2012, 26, 1403-1413.	1.0	30
157	What Might be the Impact of Sexual Partnership "Concurrency―Behavior Change Communication Campaigns?. Sexually Transmitted Diseases, 2012, 39, 899.	0.8	0
158	Mathematical models in the evaluation of health programmes. Lancet, The, 2011, 378, 515-525.	6.3	202
159	Towards an improved investment approach for an effective response to HIV/AIDS. Lancet, The, 2011, 377, 2031-2041.	6.3	424
160	Estimating HIV Incidence among Adults in Kenya and Uganda: A Systematic Comparison of Multiple Methods. PLoS ONE, 2011, 6, e17535.	1.1	53
161	Estimating the HIV incidence rate: recent and future developments. Current Opinion in HIV and AIDS, 2011, 6, 102-107.	1.5	44
162	Concurrent Sexual Partnerships and Primary HIV Infection: A Critical Interaction. AIDS and Behavior, 2011, 15, 687-692.	1.4	116

#	Article	IF	CITATIONS
163	Will circumcision provide even more protection from HIV to women and men? New estimates of the population impact of circumcision interventions. Sexually Transmitted Infections, 2011, 87, 88-93.	0.8	84
164	Condom use by female sex workers and their clients in Mexico: who decides and does it matter?. Sexually Transmitted Infections, 2011, 87, 254-256.	0.8	4
165	Optimal Uses of Antiretrovirals for Prevention in HIV-1 Serodiscordant Heterosexual Couples in South Africa: A Modelling Study. PLoS Medicine, 2011, 8, e1001123.	3.9	130
166	Evidence for changes in behaviour leading to reductions in HIV prevalence in urban Malawi. Sexually Transmitted Infections, 2011, 87, 296-300.	0.8	15
167	A Surprising Prevention Success: Why Did the HIV Epidemic Decline in Zimbabwe?. PLoS Medicine, 2011, 8, e1000414.	3.9	137
168	Estimating the risk of HIV transmission from homosexual men receiving treatment to their HIV-uninfected partners. Sexually Transmitted Infections, 2011, 87, 17-21.	0.8	24
169	Estimates of HIV incidence from household-based prevalence surveys. Aids, 2010, 24, 147-152.	1.0	54
170	Patterns of Self-reported Behaviour Change Associated with Receiving Voluntary Counselling and Testing in a Longitudinal Study from Manicaland, Zimbabwe. AIDS and Behavior, 2010, 14, 708-715.	1.4	50
171	A Decline in New HIV Infections in South Africa: Estimating HIV Incidence from Three National HIV Surveys in 2002, 2005 and 2008. PLoS ONE, 2010, 5, e11094.	1.1	119
172	HIV decline in Zimbabwe due to reductions in risky sex? Evidence from a comprehensive epidemiological review. International Journal of Epidemiology, 2010, 39, 1311-1323.	0.9	121
173	Measuring and correcting biased child mortality statistics in countries with generalized epidemics of HIV infection. Bulletin of the World Health Organization, 2010, 88, 761-768.	1.5	17
174	Examining the promise of HIV elimination by â€~test and treat' in hyperendemic settings. Aids, 2010, 24, 729-735.	1.0	237
175	HIV and risk environment for injecting drug users: the past, present, and future. Lancet, The, 2010, 376, 268-284.	6.3	459
176	Is antiretroviral therapy modifying the HIV epidemic?. Lancet, The, 2010, 376, 1824-1825.	6.3	15
177	Short Communication: Prioritizing Communities for HIV Prevention in sub-Saharan Africa. AIDS Research and Human Retroviruses, 2010, 26, 401-405.	0.5	12
178	Estimating HIV Incidence in Populations Using Tests for Recent Infection: Issues, Challenges and the Way Forward. Journal of HIV AIDS Surveillance & Epidemiology, 2010, 2, 1-14.	5.0	70
179	Estimating Incidence of HIV Infection in Uganda. JAMA - Journal of the American Medical Association, 2009, 301, 159.	3.8	5
180	Monitoring HIV epidemics: declines in prevalence do not always mean good news. Aids, 2009, 23, 131-132.	1.0	4

#	Article	IF	CITATIONS
181	Assessing evidence for behaviour change affecting the course of HIV epidemics: A new mathematical modelling approach and application to data from Zimbabwe. Epidemics, 2009, 1, 108-117.	1.5	80
182	Errors in â€~BED'-Derived Estimates of HIV Incidence Will Vary by Place, Time and Age. PLoS ONE, 2009, 4, e5720.	1.1	57
183	Estimating Incidence from Prevalence in Generalised HIV Epidemics: Methods and Validation. PLoS Medicine, 2008, 5, e80.	3.9	117
184	The Impact of Monitoring HIV Patients Prior to Treatment in Resource-Poor Settings: Insights from Mathematical Modelling. PLoS Medicine, 2008, 5, e53.	3.9	25
185	Late Entry to HIV Care Limits the Impact of Anti-Retroviral Therapy in the Netherlands. PLoS ONE, 2008, 3, e1949.	1.1	32
186	Understanding the Impact of Male Circumcision Interventions on the Spread of HIV in Southern Africa. PLoS ONE, 2008, 3, e2212.	1.1	122
187	Appropriate evaluation of HIV prevention interventions: from experiment to full-scale implementation. Sexually Transmitted Infections, 2007, 83, i55-i60.	0.8	50
188	Age at First Sex and HIV Infection in Rural Zimbabwe. Studies in Family Planning, 2007, 38, 1-10.	1.0	63
189	HIV Decline Associated with Behavior Change in Eastern Zimbabwe. Science, 2006, 311, 664-666.	6.0	286
190	Adult HIV mortality in Zimbabwe. Bulletin of the World Health Organization, 2006, 84, 189-197.	1.5	31
191	How to Pay 'Cash-on-Delivery' for HIV Infections Averted: Two Measurement Approaches and Ten Payout Functions. SSRN Electronic Journal, 0, , .	0.4	2
192	How to Pay †Cash-on-Delivery†for HIV Infections Averted: Two Measurement Approaches and Ten Payout Functions. SSRN Electronic Journal, 0, , .	0.4	1